现代检验医学杂志2025，Vol.40Issue(5)：11-15,5.DOI:10.3969/j.issn.1671-7414.2025.05.003
晚期或复发胃癌患者系统免疫炎症指数与控制营养状态评分对免疫联合化疗效果的预测价值
Predictive Value of SII and CONUT Score in Immune Combined Chemotherapy in Patients with Advanced or Recurrent Gastric Cancer
摘要
Abstract
Objective To explore the predictive value of systemic immune-inflammation index(SII)and control of nutritional status(CONUT)score for the efficacy of immune combined chemotherapy in patients with advanced or recurrent gastric cancer.Methods A retrospective analysis was conducted on the clinical data of 143 patients with advanced or recurrent gastric cancer who underwent immune combined chemotherapy as a treatment regimen at Huangshan People's Hospital from January 2020 to December 2023.The patients were divided into a disease control group(n=105)and a disease non-control group(n=38)according to the response evaluation criteria in solid tumor(RECIST).The CONUT score and SII levels between the two groups were compared.Multivariate Logistic regression analysis was used to identify the factors influencing the efficacy of immune combined chemotherapy in patients with advanced or recurrent gastric cancer.Receiver operating characteristic(ROC)curves were employed to predict the value of pre-treatment CONUT score,SII,and their combination in predicting the efficacy of immune-combined chemotherapy for advanced or recurrent gastric cancer.Results The CONUT score(2.8±0.5)and SII level(1 073.64±141.26)in the disease control group under than those in the disease non-control group(3.3±0.7,1 183.27±186.34),and the differences were statistically significant(t=4.721,3.751,all P<0.05).Multivariate Logistic regression analysis revealed that age,degree of differentiation,maximum diameter of measurable lesions,CONUT score,and SII were all factors influencing the treatment outcome in patients with advanced or recurrent gastric cancer(Wald χ2=5.161～22.758,all P<0.05).The ROC curve results showed that the AUC(95%CI)for pre-treatment CONUT score,SII,and their combination in predicting the efficacy of immuno chemotherapy in patients with advanced or recurrent gastric cancer were 0.746(0.667～0.815),0.839(0.768～0.895)and 0.875(0.809～0.924),respectively,with sensitivities of 73.11%,76.32%and 79.68%,and specificities of 91.43%,82.86%and 84.75%,respectively.Conclusion CONUT score and SII are influencing factors for the efficacy of immuno-combined chemotherapy in patients with advanced or recurrent gastric cancer,and their combination demonstrates good predictive value for the treatment outcome.关键词
晚期或复发胃癌/系统免疫炎症指数/控制营养状态评分/免疫联合化疗Key words
advanced or recurrent gastric cancer/systemic immune-inflammation index/controlled nutritional status score/immune-combined chemotherapy分类
医药卫生引用本文复制引用
吴鹏飞,吴怡青,汪曙红,王根和..晚期或复发胃癌患者系统免疫炎症指数与控制营养状态评分对免疫联合化疗效果的预测价值[J].现代检验医学杂志,2025,40(5):11-15,5.基金项目
国家自然科学基金(82373294). （82373294）
